Warning Letters Special Report: The Decline And Fall Of Morton Grove Pharmaceuticals
It was bad enough that out-of-specification investigations were hugely inadequate, but the firm’s response to the FDA’s findings was even worse.

It was bad enough that out-of-specification investigations were hugely inadequate, but the firm’s response to the FDA’s findings was even worse.